Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
T-Rex 2x Inverse Tesla Daily Target ETF
TSLZ
US Stock MarketDetailed Quotes
SAGE Sage Therapeutics
- 7.770
- -0.020-0.26%
Close Apr 28 16:00 ET
- 7.770
- 0.0000.00%
Post 16:20 ET
486.56MMarket Cap-1.18P/E (TTM)
7.860High7.690Low565.04KVolume7.770Open7.790Pre Close4.38MTurnover1.12%Turnover RatioLossP/E (Static)62.62MShares14.30952wk High1.05P/B391.63MFloat Cap4.62052wk Low--Dividend TTM50.40MShs Float195.970Historical High--Div YieldTTM2.18%Amplitude4.620Historical Low7.754Avg Price1Lot Size
About Sage Therapeutics Company
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Company Profile
SymbolSAGE
Company NameSage Therapeutics
Listing DateJul 18, 2014
Issue Price18.00
Founded2010
CEOMr. Barry E. Greene
MarketNASDAQ
Employees353
Fiscal Year Ends12-31
Address55 Cambridge Parkway
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-299-8380
Websitehttp://www.sagerx.com
Company Executives
- Name
- Position
- Salary
- Barry E. Greene
- Director, President and Chief Executive Officer
- 7.11M
- Christopher Benecchi
- Chief Operating Officer, Treasurer, Principal Financial and Accounting Officer
- 2.60M
- Dr. Mike Quirk, PhD
- Chief Scientific Officer
- --
- Gregory L. Shiferman
- Senior Vice President, General Counsel and Secretary
- --
- Geno J. Germano
- Chairman of the Board
- 190.49K
- Jessica J. Federer
- Independent Director
- 151.67K
- Elizabeth Barrett
- Independent Director
- 159.31K
- Michael F. Cola
- Independent Director
- 167.22K
- James M. Frates
- Independent Director
- 169.31K
- Dr. George S. Golumbeski, PhD
- Independent Director
- 146.81K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
